Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

Board, R E; Ellison, G; Orr, M C M; Kemsley, K R; McWalter, G; Blockley, L Y; Dearden, S P; Morris, C; Ranson, M; Cantarini, M V; Dive, C; Hughes, A

Board, R E; Ellison, G; Orr, M C M; Kemsley, K R; McWalter, G; Blockley, L Y; Dearden, S P; Morris, C; Ranson, M; Cantarini, M V; Dive, C; Hughes, A.

Affiliation

Board RE; AstraZeneca Pharmaceuticals, Alderley Park, Cheshire SK10 4TG, UK.

Br J Cancer ; 101(10): 1724-30, 2009 Nov 17.

Article in En | MEDLINE | ID: mdl-19861964

Subject(s)

Benzimidazoles/therapeutic use; Melanoma/drug therapy; Melanoma/genetics; Mutation; Proto-Oncogene Proteins B-raf/genetics; Skin Neoplasms/drug therapy; Skin Neoplasms/genetics; Antineoplastic Agents/pharmacology; Antineoplastic Agents/therapeutic use; Cell Line, Tumor; DNA Mutational Analysis; DNA, Neoplasm/blood; DNA, Neoplasm/genetics; Disease-Free Survival; HT29 Cells; Humans; Melanoma/blood; Melanoma/metabolism; Prognosis; Proto-Oncogene Proteins B-raf/metabolism; Skin Neoplasms/blood; Skin Neoplasms/metabolism

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Benzimidazoles / Proto-Oncogene Proteins B-raf / Melanoma / Mutation Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Br J Cancer Year: 2009 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google